Achillion Pharmaceuticals (ACHN) : Simplex Trading scooped up 15,430 additional shares in Achillion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 32,439 shares of Achillion Pharmaceuticals which is valued at $252,700.Achillion Pharmaceuticals makes up approximately 0.03% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in ACHN in the latest quarter, The investment management firm added 5,137 additional shares and now holds a total of 9,692 shares of Achillion Pharmaceuticals which is valued at $78,311.
Achillion Pharmaceuticals closed down -0.08 points or -1.02% at $7.79 with 10,37,707 shares getting traded on Friday. Post opening the session at $7.89, the shares hit an intraday low of $7.66 and an intraday high of $7.925 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Achillion Pharmaceuticals reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. FBR & Co. Initiated Achillion Pharmaceuticals on Sep 15, 2016 to “Outperform”, Price Target of the shares are set at $16.Chardan Capital Markets Initiated Achillion Pharmaceuticals on Jul 14, 2016 to “Sell”, Price Target of the shares are set at $4.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.